Bio Farma Wins Indonesia Most Reputable Companies Award 2026, Reinforcing Reputation Built on Capability and Trust



Bandung, September 11, 2026 – Bio Farma has been recognized with the Indonesia Most Reputable Companies Award 2026 and Indonesia Most Reputable Companies Champions Excellence 2026, presented by SWA and Business Digest. The awards were presented at the *Conference & Awarding* event themed *"Strengthening Corporate Reputation and Employee Engagement in the Age of Rising Stakeholders Expectation"* on September 10, 2026, in Jakarta.

The awards recognize Bio Farma's consistent efforts to build and maintain stakeholder trust. Over its 136-year history, Bio Farma's reputation has grown alongside its contribution to Indonesia's national immunization programs, while strengthening the global recognition and trust in Indonesia's healthcare industry.

SWA Editor-in-Chief Kemal Effendi Gani said that corporate reputation is built over time and cannot be established overnight.

"Reputation is the accumulation of the behaviors and decisions we make. A good reputation is not built overnight; it must be maintained every day, especially in the social media era. We congratulate all the award recipients. Let us work together to build not only profitable companies, but also trusted ones—not only large companies, but companies that people can trust and be proud of," said Kemal.

This view reflects Bio Farma's journey in building trust through consistent performance, strong capabilities, and tangible contributions to society. As it marks its 136th year, Bio Farma continues to

transform from a vaccine manufacturer into a life science company focused on innovation and healthcare solutions.

President Director of Bio Farma, Shadiq Akasya, emphasized that reputation cannot be built through communication alone. It must be supported by proven capabilities and benefits that people can experience.

“Reputation is not built through communication alone, but through real capabilities. For Bio Farma, the trust built over 136 years must continue to be demonstrated through product quality, innovation, the ability to meet global standards, and our commitment to ensuring that healthcare products reach the people who need them,” said Shadiq.

A key foundation of Bio Farma’s reputation is its ability to meet the stringent international standards of the vaccine industry. More than 20 Bio Farma products have received WHO Prequalification (WHO PQ), enabling them to be used in international health programs, including through UNICEF procurement mechanisms.

This achievement demonstrates the capability of Indonesia’s healthcare industry to develop products that meet global standards for safety, quality, and efficacy. Meeting international requirements while gaining access to global markets also demonstrates the competitiveness of healthcare products developed and manufactured in Indonesia and their potential to contribute to global public health.

For Bio Farma, this trust comes with greater responsibility. A pharmaceutical company’s reputation does not end when a product is manufactured. Quality and trust must be maintained throughout the supply chain until the product reaches and is used by the public.

“A pharmaceutical company’s reputation does not end when a product is manufactured. It is put to the test when the product is distributed and reaches the public. Therefore, maintaining quality from upstream to downstream is an integral part of our commitment to preserving trust,” Shadiq added.

The Indonesia Most Reputable Companies 2026 award recognizes reputation not merely as a matter of corporate image, but as a reflection of public perceptions of company performance and its relationships with stakeholders. SWA and Business Digest conducted a survey involving 5,000 respondents who were customers across various product and service categories. In addition to the survey, this year’s judging process involved 14 participating companies.

The assessment was based on four key dimensions: *Product & Services, Corporate Credibility, Value & Program,* and *People & Relationship*. These dimensions reflect how reputation is shaped by product and service quality, corporate credibility, the value and programs delivered, and the quality of relationships with stakeholders.

“This award is not only recognition of what we have achieved, but also a responsibility to continue earning and maintaining trust. Reputation must be demonstrated every day through what we deliver and the benefits people experience. We want Indonesia’s healthcare industry to gain greater trust, not only domestically but also globally,” Shadiq concluded.

As part of the Danantara ecosystem, Bio Farma views reputation and trust as important assets in strengthening its role as a strategic national asset. By improving performance and the competitiveness of the healthcare industry, Bio Farma continues to expand health benefits for society while supporting greater national health resilience.

In line with the spirit of “Advancing Hope, Shaping The Future,” Bio Farma continues to leverage its

capabilities, assets, and innovation to create greater value for Indonesia. This contribution is realized through healthcare products and solutions that improve people's quality of life, strengthen the performance of strategic national industries, and create long-term value through innovation and sustainable growth, with governance and integrity as its foundation.

For Bio Farma, reputation is ultimately not only about how the company is perceived, but about how consistently it delivers meaningful benefits, maintains trust, and creates sustainable value for Indonesia and future generations.

—o0o—

For Further Information, Please Contact :
Corporate Communications
PT Bio Farma (Persero)
corcom@biofarma.co.id